BMSSC
BBIO icon

B. Metzler seel. Sohn & Co’s BridgeBio Pharma BBIO Stock Holding History

B. Metzler seel. Sohn & Co’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.3M Hold
17,506
– – 0.01% 522
2026
Q1 		$1.3M Hold
17,506
– – 0.01% 483
2025
Q4 		$1.34M Sell
17,506
-7,245
-29% -$476K 0.01% 490
2025
Q3 		$1.29M Sell
24,751
-11,852
-32% -$578K 0.01% 495
2025
Q2 		$1.58M Hold
36,603
– – 0.02% 433
2025
Q1 		$1.27M Hold
36,603
– – 0.01% 467
2024
Q4 		$1M Hold
36,603
– – 0.01% 536
2024
Q3 		$932K Buy
36,603
+7,514
+26% +$197K 0.01% 558
2024
Q2 		$737K Hold
29,089
– – 0.01% 580
2024
Q1 		$899K Sell
29,089
-19,723
-40% -$671K 0.01% 538
2023
Q4 		$1.97M Buy
48,812
+5,213
+12% +$157K 0.03% 370
2023
Q3 		$1.15M Sell
43,599
-37,957
-47% -$1.08M 0.02% 438
2023
Q2 		$1.4M Buy
81,556
+27,919
+52% +$420K 0.02% 436
2023
Q1 		$889K Buy
53,637
+4,367
+9% +$50.9K 0.01% 457
2022
Q4 		$375K Hold
49,270
– – 0.01% 597
2022
Q3 		$490K Buy
49,270
+2,624
+6% +$27.3K 0.01% 545
2022
Q2 		$424K Hold
46,646
– – 0.01% 579
2022
Q1 		$473K Buy
+46,646
New +$479K 0.01% 606

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

B. Metzler seel. Sohn & Co's BBIO Position: Q2 2026 in Review

B. Metzler seel. Sohn & Co held its BridgeBio Pharma (BBIO) position steady in Q2 2026 at 17,506 shares worth $1.3M. The position accounts for 0.01% of the portfolio, ranked #522.

B. Metzler seel. Sohn & Co first reported a position in BBIO in Q1 2022 and has held it in 18 quarters since. The position peaked at $1.97M in Q4 2023. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • B. Metzler seel. Sohn & Co held 17,506 shares of BridgeBio Pharma worth $1.3M as of Q2 2026.
  • B. Metzler seel. Sohn & Co left its BridgeBio Pharma share count unchanged in Q2 2026.
  • BridgeBio Pharma made up 0.01% of B. Metzler seel. Sohn & Co's portfolio in Q2 2026, its #522 holding.
  • B. Metzler seel. Sohn & Co first reported a position in BridgeBio Pharma in Q1 2022 and has held it in 18 quarters since.
  • B. Metzler seel. Sohn & Co's BridgeBio Pharma position peaked at $1.97M in Q4 2023.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on B. Metzler seel. Sohn & Co's 13F filing for Q2 2026, filed 11 Aug 2026.